DREAMSeq Trial Clarifies Optimal Sequencing in BRAF V600–Mutant Melanoma

Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.

Andrew L. Pecora, MD, discusses the key efficacy findings from the phase 3 DREAMSEQ trial in BRAF-mutated melanoma.

Findings from the DREAMseq trial indicate that nivolumab plus ipilimumab should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.